Page 9 - Q3 Results

State Bank of India books over Rs 14,000-cr profit in its best performance

A healthy rise in NII and a sharp drop in credit costs boost bottom-line

ITC Q3 net profit rises 23.4% to Rs 5,006 cr on growth across segments

Revenues from the non-cigarettes FMCG segment was at Rs 4,848.95 crore compared to Rs 4,099.47 crore

IndiGo flies back in green, Q3 net soars 1,000% to a record Rs 1,422 cr

Record Rs 1,422-cr quarterly profit comes on the back of best-ever revenue

Rising demand, better chip supplies powering TaMo's ride out of losses

Growing global and domestic demand, better semiconductor chip supplies, and softening commodity prices are powering the automotive manufacturer's ride out of losses

Emami net profit up 7.8% at Rs 237.13 cr, says rural demand slowing

Domestic business grows one per cent in the quarter; international by 7%

ITC Q3 PAT up 12% to Rs 5,031 cr, declares interim dividend of Rs 6/share

Revenue from operations increased by 0.8% to Rs 17,122.15 crore from Rs 16,971.18 crore in the previous fiscal quarter

Zydus Lifesciences net profit rises 24.48% to Rs 622.9 cr in Dec quarter

Zydus Lifesciences Ltd on Friday reported a 24.48 per cent rise in consolidated net profit at Rs 622.9 crore for the third quarter ended December 31, 2022. The company had posted a consolidated net profit of Rs 500.4 crore in the same period last fiscal, Zydus Lifesciences Ltd said in a regulatory filing. Consolidated total revenue from operations during the quarter under review stood at Rs 4,362.3 crore, as against Rs 3,639.8 crore in the year-ago period, it added. Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal. In the third quarter, its business in India comprising formulations as well as consumer wellness registered revenues of Rs 1,643.6 crore, up 13 per cent, while the US formulations business registered revenues of Rs 1,925 crore, up 29 per cent from the year-ago period, the company said. Emerging markets formulations business registered revenues of Rs 307.8 crore, up 15 per cent an

SBI Q3 result: Net profit soars 69% YoY to Rs 14,205 crore, beats estimates

SBI Q3 result: The profit number beat Street estimate. Consensus estimates by Bloomberg had projected net profit at Rs 13,196 crore

India Cements Q3 net up seven fold to Rs 133 crore on sale of subsidiary

Revenue rises 10%; company lines up Rs 1,600 cr plan to revamp old plants

Sensex zooms 910 pts as financials defy Adani rout; Nifty ends above 17,850

Closing Bell: On the Nifty, Adani Ports closed in green after two days with a firm gain of 6 per cent., while Adani Enterprises erased over 50 per cent of its day's losses to close 2 per cent down

Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected

In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall in revenue

Bank of Baroda reports highest-ever quarterly profit of Rs 3,853 cr in Q3

On the bourses, shares of the bank jumped over 5 per cent to an intra-day high of Rs 162.3 per share

Titan rallies 5% on hopes of healthy Q4 business outlook

Given strong execution, analysts at Emkay Global Financial Services, too, remain confident of the high-teens earnings trajectory for Titan in the medium term

Stocks to Watch: Adani Group, SBI, Paytm, BoB, HDFC AMC, Auto, SBI Life

Stocks to watch today: The National Stock Exchange (NSE) on Thursday shifted Adani Enterprises, Adani Ports, and Ambuja Cements to a category of stocks that require up to 100 per cent trading margins

Max Healthcare Q3 PAT up 7% to Rs 269 cr, revenue rises to Rs 1,559 cr

Max Healthcare Institute on Thursday reported a 7 per cent increase in its consolidated profit after tax at Rs 269 crore for the December quarter. The healthcare provider had posted a profit after tax of Rs 252 crore in the October-December period of last fiscal. Network gross revenue increased to Rs 1,559 crore, reflecting a 13 per cent year-on-year growth, Max Healthcare said in a statement. "By virtue of focus on healthcare infrastructure, research and skilling as well as ground breaking policies such as National Digital Healthcare Mission, Heal In India and Heal By India, the government has established a solid foundation to enable the private sector players in India to cater to both domestic and global requirements at affordable prices," Max Healthcare Institute Chairman and MD Abhay said. Shares of the company ended 0.23 per cent down at Rs 440.4 apiece on the BSE.

Airtel Africa Q3 net profit rises 7.5% to Rs 1,586 cr, revenue up 10.7%

Telecom operator Bharti Airtel said its African arm Airtel Africa on Thursday posted a 7.5 per cent growth in profit after tax at USD 193 million, about Rs 1,586 crore, in the third quarter ended December 2022. The company had posted a profit after tax (PAT) of USD 180 million in the same period a year ago. "Providing affordable, innovative and essential services to customers in our 14 markets with unparalleled network quality and customer service is integral to our ambition of transforming lives across Africa. These strong results are testament to this strategy despite the current macro-economic and geopolitical uncertainties," Aitel Africa Chief Executive Officer Segun Ogunsanya said in a statement. The revenue of Airtel Africa during the reported quarter increased by 10.7 per cent to USD 1,350 million from USD 1,219 million in December 2021 quarter. In constant currency term, revenue of Airtel Africa grew 18 per cent. Total customer base of Airtel Africa increased by 10.1 per c

HDFC Q3 net profit rises 13% to Rs 3,691 crore, impairments decline

Monetary policy, interest rate actions had short-term impact on net interest income, says mortgage major

Q3 results: Titan posts surprise net profit fall, shares sink over 1%

The quarter witnessed a strong festive consumer demand, Titan Company Managing Director C K Venkataraman said

Alembic Pharma Q3 net dips 29% to Rs 122 cr, revenue rises to Rs 1,509 cr

Alembic Pharmaceuticals on Thursday said its consolidated net profit declined by 29 per cent to Rs 122 crore in the December quarter. The Vadodara-based drug maker had reported a net profit of Rs 172 crore in the October-December quarter of last fiscal. Revenue from operations rose to Rs 1,509 crore in the period under review from Rs 1,272 crore in the year-ago period, Alembic Pharmaceuticals said in a statement. "The company witnessed top-line growth across all the verticals. In particular, the API business outperformed with a 65 per cent growth during the quarter," Alembic Pharmaceuticals Managing Director Pranav Amin stated.

Mahindra Lifespaces Q3 net up 33% to Rs 33.21 cr, income rises to Rs 198 cr

Realty firm Mahindra Lifespace Developers Ltd on Thursday reported a 33 per cent increase in its consolidated net profit at Rs 33.21 crore for the quarter ended December. Its net profit stood at Rs 25.02 crore in the year-ago period. Total income rose sharply to Rs 198.14 crore in the third quarter of the current financial year from Rs 33.32 crore a year ago, according to a regulatory filing. Net profit during the April-December period of this fiscal jumped to Rs 100.88 crore from Rs 17.67 crore in the corresponding period of the previous year. Total income also rose to Rs 389.30 crore in the first nine months of FY23 from Rs 253.22 crore in the same period last year. Mahindra Lifespace, which is part of Mahindra Group, is one of the leading real estate firms in the country.